Jeffrey Keats

Blueprint Medicines (United States) — United States

Medicine · Health Sciences

14h-index2.3kcitations25works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Treatments and Mutations(6), Chronic Lymphocytic Leukemia Research(6), Chronic Myeloid Leukemia Treatments(6), Lung Cancer Research Studies(4), Eosinophilic Disorders and Syndromes(3)

Publications25 total

Abstract C151: BLU-451 is a CNS-penetrant, wild-type-sparing EGFR inhibitor with broad coverage of uncommon EGFR mutations across structure-based subsets
Molecular Cancer Therapeutics·2023
Abstract 1161: EZH2 inhibitor tazemetostat demonstrates activity in preclinical models of Bruton's tyrosine kinase inhibitor-resistant relapsed/refractory mantle cell lymphoma
Cancer Research·2021· 3 cited
Abstract B011: Synergistic activity of tazemetostat in combination with androgen signaling inhibitors in preclinical models of prostate cancer demonstrates potential for clinical expansion
Molecular Cancer Therapeutics·2019· 1 cited
Abstract 1944: Tazemetostat displays synergistic antiproliferative activity with backbone therapies in preclinical models of AT/RT and MRT
Cancer Research·2017· 1 cited
Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase
Journal of Medicinal Chemistry·2016· 393 citedOpen Access
Abstract B82: Pinometostat (EPZ-5676) enhances the antiproliferative activity of MAP kinase pathway inhibitors in <i>MLL</i>-rearranged leukemia cell lines
Molecular Cancer Therapeutics·2015· 3 cited
Abstract 5383: DOT1L inhibitor EPZ-5676 synergizes with cytarabine and azacitidine in preclinical models of MLL-rearranged leukemia
Cancer Research·2015
Abstract 1794: AP26113 is a dual ALK/EGFR inhibitor: Characterization against EGFR T790M in cell and mouse models of NSCLC
Cancer Research·2012· 41 cited
Crizotinib‐Resistant Mutants of EML4‐ALK Identified Through an Accelerated Mutagenesis Screen
Chemical Biology & Drug Design·2011· 131 citedOpen Access
Abstract 3623: Efficacy and pharmacodynamic analysis of AP26113, a potent and selective orally active inhibitor of Anaplastic Lymphoma Kinase (ALK)
Cancer Research·2010· 27 cited
Abstract LB-298: AP26113, a potent ALK inhibitor, overcomes mutations in EML4-ALK that confer resistance to PF-02341066 (PF1066)
Cancer Research·2010· 50 cited
AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance
Cancer Cell·2009· 1.2k citedOpen Access
Abstract #3738: Discovery of potent and selective orally active inhibitors of anaplastic lymphoma kinase (ALK)
Cancer Research·2009· 11 cited
Potent Antitumor Activity of AP24534, An Orally Active Inhibitor of Bcr-Abl, Flt3 and Other Kinases, in Both in Vitro and in Vivo Models of Acute Myeloid Leukemia (AML)
Blood·2008· 8 cited
Novel N9-arenethenyl purines as potent dual Src/Abl tyrosine kinase inhibitors
Bioorganic & Medicinal Chemistry Letters·2008· 32 citedOpen Access
Potent Antitumor Activity of AP24534, an Orally Active Inhibitor of Bcr-Abl Variants Including T315I, in In Vitro and In Vivo Models of Chronic Myeloid Leukemia (CML).
Blood·2007· 21 cited
Index
2007Open Access
Bone-targeted rapamycin analogs inhibit osteolysis and tumor growth in a PC-3-GFP intratibial bone cancer model in nude mice
Cancer Research·2006
AP23846, a novel and highly potent Src family kinase inhibitor, reduces vascular endothelial growth factor and interleukin-8 expression in human solid tumor cell lines and abrogates downstream angiogenic processes
Molecular Cancer Therapeutics·2005· 79 cited
Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML
Blood·2004· 198 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

William C. Shakespeare(15), David C. Dalgarno(14), Tim Clackson(13), Victor M. Rivera(12), Frank Wang(11), Yihan Wang(11), Scott Wardwell(10), Chester A. Metcalf(9), Yaoyu Ning(9), Raji Sundaramoorthi(9), Tomi K. Sawyer(9), Narayana I. Narasimhan(7), Xiaotian Zhu(6), Qihong Xu(6), Shuangying Liu(6), Rana Anjum(6), Lauren Moran(6), Regine S. Bohacek(6), Mathew Thomas(5), J. T. Snodgrass(5)